This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, as part of an alliance between Merck KGaA and Pfizer.
Reference
Bhanegaonkar A, et al. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy. Advances in Therapy : 17 Apr 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01657-2
Rights and permissions
About this article
Cite this article
Metastatic renal-cell carcinoma treated with first-line monotherapy: considerable burden, high unmet needs. PharmacoEcon Outcomes News 877, 13 (2021). https://doi.org/10.1007/s40274-021-7662-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7662-7